This Solution Provider Webinar is brought to you by DIA in cooperation with

Multicancer early detection (MCED) tests have generated great enthusiasm and are becoming available in the U.S. Well-designed clinical trials are needed to determine whether they truly improve health outcomes or if they increase cancer diagnosis rates without ultimately saving lives. In addition, during a trial, if MCED testing leads to increased demand for limited follow-up services such as imaging or endoscopy, this could lead to increased wait times, delayed diagnosis, and worse outcomes for control group patients in the same health system. Trials evaluating MCED and other technologies that affect care delivery should be designed to account for such spillover effects, or they risk overestimating intervention benefits.